Biography

1. Research Areas

Tumor pathology and Molecular Biology, Cell Signaling, Tumor Epigenetics

2. Education

2003.09-2007.12, Ph.D., Biochemistry and Molecular Biology, Nankai University

1999.09-2001.07, M.M., Clinical Medicine, Nankai University

1994.09-1999.07, M.B., Clinical Medicine, Nankai University

3. Professional Experience

2015.12-Present, Professor in School of Medicine, Nankai University

2010.02-2011.02, Postdoctoral Fellow in Boston Children’s Hospital, Harvard Medical School

2009.12-2015.12, Associate Professor in School of Medicine, Nankai University

2004.12-2009.12, Lecture in School of Medicine, Nankai University

2001.07-2001.10, Research Fellow in Bone Research, Procter & Gamble Pharmaceuticals

2001.09-2004.12, Assistant in School of Medicine, Nankai University

4. Awards

[1]2012.05, The Science and Technology Awards of CACA (Third Prize), Chinese Anti-Cancer Association

[2]2011.11, Program for New Century Excellent Talents in University, Ministry of Education of China

[3]2010.04, Scholar-in-Training Awards, American Association for Cancer Research

[4]2009.07, Program of Study Abroad for Young Scholar, China Scholarship Council

[5]2004.09, Web Jee Young Investigator Awards, International Chinese Hard Tissue Society

5. Social Service

[1]2015-Present, Board Member, Tianjin Society for Immunology

[2]2011-Present, Board Member, Tianjin Society for Cell Biology

[3]2009-Present, Member, American Association for Cancer Research

[4]2004-Present, Member, China Society for Cell Biology

[5]2012-Present, Member, International Chinese Hard Tissue Society

Research & Achievements

Peer-Reviewed Journal Papers: (*Corresponding author)

[1]Zhang J, Liu C, Shi W, Yang L, Zhang Q, Cui J, Fang Y, Li Y, Ren G, Yang S*, Xiang R. (2016) The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer. Oncotarget 7: 41067-41080.

[2]Liu Y, Wang Z, Huang D, Wu C, Li H, Zhang X, Meng B, Li Z, Zhu T, Yang S*, Sun W. LMO2 promotes tumor cell invasion and metastasis in basal-type breast cancer by altering actin cytoskeleton remodeling. Oncotarget 2016 Nov 17. [Epub ahead of print]

[3]Luo D, Wang G, Shen W, Zhao S, Zhou W, Wan L, Yuan L, Yang S*, Xiang R. (2016) Clinical significance and functional validation of PPA1 in various tumors. Cancer Medicine 5: 2800-2812.

[4]Liu Y, Huang D, Wang Z, Wu C, Zhang Z, Wang D, Li Z, Zhu T, Yang S, Sun W. (2016) LMO2 attenuates tumor growth by targeting the Wnt signaling pathway in breast and colorectal cancer. Scientific Reports 6: 36050.

[5]Wu C, Liu Y, Gu X, Zhu T, Yang S*, Sun W. (2016) LMO2 blocks the UBA6-USE1 interaction and downstream FAT10ylation by targeting the ubiquitin fold domain of UBA6. Biochemical and Biophysical Research Communications 478: 1442-1448.

[6]Liu L, Tong Q, Liu S, Cui J, Zhang Q, Sun W, Yang S*. (2016) ZEB1 Upregulates VEGF Expression and Stimulates Angiogenesis in Breast Cancer. PLoS One 11: e0148774.

[7]Chang A, Chen Y, Shen W, Gao R, Zhou W, Yang S, Liu Y, Luo Y, Chuang TH, Sun P, Liu C, Xiang R. (2015) Ifit1 Protects Against Lipopolysaccharide and D-galactosamine-Induced Fatal Hepatitis by Inhibiting Activation of the JNK Pathway. The Journal of infectious diseases 212: 1509-1520.

[8]Yang S*, Liu LJ, Xu PJ, Yang Z*. (2015) MKL1 Inhibits Cell Cycle Progression through p21 in Podocytes. BMC Molecular Biology 16: 1.

[9]Hu F,Wang K,Zhang Y,Gou L,Luo M,Zhang X,Yang S*. (2014) δEF1 upregulates CDK4 transcription via the E2-box element on the CDK4 promoter. Experimental and therapeutic medicine7: 161-164.

[10]Hu F,Meng X,Tong Q,Liang L,Xiang R,Zhu T,Yang S*. (2013) BMP-6 inhibits cell proliferation by targeting microRNA-192 in breast cancer. Biochimica et Biophysica Acta-Molecular Basis of Disease1832: 2379-2390.

[11]Guo SC, Li YQ, Tong Q, Gu F, Zhu TH, Fu L, Yang S*. (2012) δEF1 down-regulates ER-α expression and renders tamoxifen resistance in breast cancer. Plos One 7: e52380.

[12]Hu F, Wang C, Guo S, Sun W, Mi D, Gao Y, Zhang J, Zhu T, Yang S*. (2011) δEF1 promotes osteolytic metastasis of MDA-MB-231 breast cancer cells by regulating MMP-1 expression. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms 1809: 200-210.

[13]Mi D, Zhang M, Yan JD, Zhang J, Wang X, Wang Q, Yang S, Zhu TH. (2011) PTHrP inhibits BMP-6 expression through the PKA signaling pathway in breast cancer cells. Journal of Cancer Research and Clinical Oncology137: 295-303.

[14]Wang C, Hu F, Guo S, Mi D, Shen W, Zhang J, Qiao Y, Zhu T, Yang S*. (2010) BMP-6 inhibits MMP-9 expression by regulating heme oxygenase-1 in MCF-7 breast cancer cells. Journal of Cancer Research and Clinical Oncology 137: 985-995.

[15]Sun W, Shen W, Yang S, Hu F, Li H, Zhu TH. (2010) miR-223 and miR-142 attenuate hematopoietic cell proliferation, and miR-223 positively regulates miR-142 through LMO2 isoforms and CEBP-β. Cell Research 20: 1158-1169.

[16]Sun W, Yang S, Shen W, Li H, Gao Y, Zhu TH. (2010) Identification of DeltaEF1 as a novel target that is negatively regulated by LMO2 in T-cell leukemia. European Journal of Haematology 85: 508-519.

[17]Sun W, Shen WW, Yang S, Hu F, Gao Y, Qiao YH, Zhu TH. (2010) Homo-binding character of LMO2 isoforms and their both synergic and antagonistic functions in regulating hematopoietic-related target genes. Journal of Biomedical Science 17: 22.

[18]Hu F, Wang C, Du J, Sun W, Yan J, Mi D, Zhang J, Qiao Y, Zhu T, Yang S*. (2010) deltaEF1 promotes breast cancer cell proliferation through down-regulating p21 expression.Biochimica et Biophysica Acta-Molecular Basis of Disease 1802: 301-312.

[19]Yang S*, Du J Wang ZQ, Yan JD, Yuan W, Zhang J, Zhu TH*. (2009) Dual Mechanism of dEF1 Expression Regulated by Bone Morphogenetic Protein-6 in Breast Cancer. The international journal of biochemistry and cell biology 41: 853-861.

[20]Du Jun, Yang S, An Di, Hu Fen, Yuan Wei, Zhai Chunli, Zhu TH. (2009) BMP-6 Inhibits MicroRNA-21 Expression through repressing delta-EF1 and AP-1 in breast cancer. Cell Research 19: 487-496.

[21]Yan JD, Yang S, Zhang J, Zhu TH. (2009) BMP6 reverses TGF-beta1-induced changes in HK-2 cells: implications for the treatment of renal fibrosis.Acta Pharmacologica Sinica 30: 994-1000.

[22]Yan J, Yang S, Zhang J, Zhai C, Zhu T. （2009） BMP6 attenuates oxidant injury in HK-2 cells via Smad-dependent HO-1 induction. Free Radic Biol Med 46: 1275-1282.

[23]Yang S, Du J, Wang ZQ, Yuan W, Qiao YH, Zhang M, Zhang J, Yin J, Gao SY, Cui YK and Zhu TH. (2007) BMP-6 promotes E-cadherin expression through repressing deltaEF1 in breast cancer cells. BMC Cancer 7: 211.

[24]Yang S, Zhao L, Yang JH, Chai DG, Zhang M, Zhang J, Ji XH, Zhu TH. (2007) DeltaEF1 represses BMP-2-induced osteoblast differentiation of C2C12 cells. Journal of Biomedical Science 14: 663-679.

[25]Du J, Yang S, Zhai CL, Yuan W, Wang ZQ, Yan JD, Zhang J, Gao SY, Sun BC and Zhu TH. (2007) Bone Morphogenetic Protein 6 Inhibit Stress-Induced Breast Cancer Cells Apoptosis via Both Smad and P38 Pathways. Journal of Cellular Biochemistry 103: 1584-1597.

[26]Sun W, Yuan W, Yang S, Du J, Zhai C, Wang Z, Zhang J, Zhu T. (2007) Down regulation of MicroRNA142 by proto-oncogene LMO2 and its co-factors in Hematopoiesis. Leukemia 22: 1067-1071.

[27]Du J, Zhu YJ, Chen XY, Fei ZJ, Yang S, Yuan W, Zhang J and Zhu TH. (2007) Protective effect of Bone Morphgenetic Protein-6 on neurons from H₂O₂ injury. Brain Research 1163:10-20.

[28]Zhang M, Wang Q, Yuan W, Yang S, Wang X, Du J, Yan JD, Zhu TH. (2007) Epigenetic Regulation of Bone morphogenetic protein-6 Gene Expression in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 105:91-97.

[29]Zhao L, Yang S, Zhou GQ, Yang JH, Sabatakos G and Zhu TH. (2006) Involvement of the cAMP-dependent protein kinase (PKA) pathway in BMP-2-induced osteoblastic differentiation of C2C12 cells. The international journal of biochemistry and cell biology 38:2064-2073.

Projects

Projects: (as Principle Investigator)

[1]Project supported by the National Nature Science Foundation of Chine: Functional Research of ZEB1 To Regulate Angiogenesis In Breast Cancer (Grant No. 81472545; 2015/01-2018/12)

[2]Project supported by the National Nature Science Foundation of Chine: δEF1-induced Anti-Estrogen Resistance in Breast Cancer (Grant No. 81272184; 2013/1-2016/12)

[3]Project supported by the National Nature Science Foundation of Tianjin: Epigenetic Regulation of δEF1 in Anti-Estrogen Resistance of Breast Cancer (Grant No. 13JCZDJC30200; 2013/4-2016/3)

[4]Project supported by the National Nature Science Foundation of Chine: BMP-6 Regulates Breast Cancer Cell Proliferation Through Targeting MicroRNA-192 (Grant No. 81072153; 2011/1-2013/12)

[5]Project supported by the National Nature Science Foundation of Tianjin: Role of BMP-6 in Inhibiting Breast Cancer Metastasis (Grant No. 09JCYBJC09100; 2009/4-2012/3)

[6]Project supported by the National Nature Science Foundation of Chine: Role of DeltaEF1 in Mediating BrMP-6-induced Transcriptional Regulation of E-cadherin (Grant No. 30700471; 2008/1-2010/12)

[7]Project supported by the National Nature Science Foundation of Chine: Role of DeltaEF1 in Osteoblast Differentiation (Grant No. 30640029; 2007/1-2007/12)

[8]Project supported by the National Nature Science Foundation of Tianjin: Expression of rhMP-6 in Eukaryotic System (Grant No. 05YFJMJC01800; 2005/4-2007/12)

Teaching

Teaching

[1]Undergraduate: Molecular Genetics of Medicine

[2]Master: Advance in Human Medical Genetics